title: Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
abstract: Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.
authors.affiliation: Department of Experimental and Clinical Sciences, University 'G. d'Annunzio', I-66013 Chieti, Italy. natoli@unich.it.
authors.forename: Antonino
authors.initials: A
authors.lastname: Grassadonia
authors.forename: Pasquale
authors.initials: P
authors.lastname: Cioffi
authors.forename: Felice
authors.initials: F
authors.lastname: Simiele
authors.forename: Laura
authors.initials: L
authors.lastname: Iezzi
authors.forename: Marinella
authors.initials: M
authors.lastname: Zilli
authors.forename: Clara
authors.initials: C
authors.lastname: Natoli